期刊文献+

B细胞淋巴瘤中Fas和FasL蛋白的表达及其意义

Protein Expressions of Fas and FasL in B-cell Lymphoma and Their Significances
暂未订购
导出
摘要 背景与目的:以往研究表明,Fas/FasL是细胞凋亡的诱导基因,有许多肿瘤的发生都与Fas/FasL功能失调及表达异常有关,本研究旨在通过对淋巴瘤及良性淋巴组织中Fas/FasL基因蛋白表达规律的研究,为诊断淋巴瘤提供新的观察指标及实验依据。方法:对确诊的92例B细胞淋巴瘤石蜡标本及20例良性淋巴组织石蜡标本用免疫组化方法进行Fas和FasL蛋白表达的检测。结果:Fas主要表达在细胞膜上。FasL主要表达在细胞浆,部分表达在细胞核。B细胞淋巴瘤中Fas蛋白总阳性率为66.3%,FasL蛋白总阳性率为67.4%,良性淋巴组织中Fas及FasL蛋白表达阳性率均为60.0%。淋巴瘤组织与良性淋巴组织之间Fas及FasL蛋白表达差异无显著性(P>0.05)。但阳性细胞在良恶性淋巴组织之间分布部位不同。淋巴瘤各亚组之间Fas及FasL蛋白表达差异有显著性(P<0.05)。Fas蛋白表达在弥漫大B细胞淋巴瘤(diffuselargeB-celllymphoma,DLBL)(87.2%)高于滤泡细胞淋巴瘤(follicularlymphoma,FL)(64.5%)及小细胞淋巴瘤(smallcelllymphoma,SLL)(31.8%);FasL蛋白表达在DLBL(89.7%)高于FL(67.7%)及SLL(27.3%)。Fas及FasL的蛋白表达与性别、年龄、部位无关。结论:Fas及FasL的阳性率不能作为鉴别B细胞淋巴瘤良恶性的指标,而Fas和FasL在良恶性细胞中分布部位不同可做为参考? BACKGROUND & OBJECTIVE: Fas and FasL have been proved to be the inductional genes of cell apoptosis. Genesis of many tumors relates with functional disorder and abnormal expressions of Fas and FasL. This study was designed to detect protein expressions of Fas and FasL in B-cell non-Hodgkin's lymphoma (B-NHL) and benign lymphoid tissue, and to provide new markers for diagnosis of lymphoma. METHODS: Immunohistochemistry was used to detect protein expressions of Fas and FasL in 92 specimens of B-NHL, and 20 specimens of benign lymphoid tissue. RESULTS: Fas mostly expressed on membrane. FasL mostly expressed in cytoplasm, and partially expressed in nuclei. Positive rate of Fas in B-NHL was 66.3% (61/92), and that of FasL in B-NHL was 67.4% (62/92). Positive rates of both Fas and FasL in benign lymphoid tissue were 60.0% (12/20). There was no significant difference in expressions of Fas and FasL between B-NHL group and benign group (P>0.05), but positive locations of Fas and FasL in these 2 groups are different. Positive rates of Fas and FasL were higher in diffuse large B-cell lymphoma (DLBL) than in follicular lymphoma (FL), and small cell lymphoma (SLL) (87.2% vs. 64.5%, and 31.8%, P<0.05; 89.7% vs. 67.7%, and 27.3%, P<0.05). Positive rates of Fas and FasL in FL were higher than those in SLL. No correlation was found between Fas/FasL expression and patients' gender, age, and tumor location. CONCLUSIONS: The expressions of Fas and FasL are not useful for distinguishing benign lymphoid tissue from lymphoma tissue, while their locational characteristics are valuable for differential diagnosis. The expressions of Fas and FasL are considered valuable in evaluating the malignant grade of B-NHL.
出处 《癌症》 SCIE CAS CSCD 北大核心 2005年第3期332-336,共5页 Chinese Journal of Cancer
基金 国家自然科学基金项目(No.39870328)~~
关键词 B细胞淋巴瘤 良性淋巴组织 FAS FASL 免疫组织化学 B-cell Lymphoma Benign lymphoid tissue Fas FasL Immunohistochemistry
  • 相关文献

参考文献13

  • 1沈宏伟,易路,汪小明,姚茂金,邓军卫,方建珍,李敏能.Caspase-3与Bcl-2蛋白在膀胱移行细胞癌中的表达及意义[J].癌症,2004,23(2):181-184. 被引量:15
  • 2Hirose Y, Masaki Y, Okada J, et al. Epstein-Barr virusassociated B-cell type non-Hodgkin's lymphoma with concurrent p53 protein expression in a rheumatoid arthritis patient treated with methotrexate [J]. Int J Hematol, 2002,75(4) :412-415.
  • 3Meda BA, Frost M, Newell J, et al. BCL-2 is consistently expressed in hyperplastic marginal zones of the spleen,abdominal lymph nodes, and ileal lymphoid tissue [J]. Am J Surg Pathol, 2003,27 (7): 888-894.
  • 4Boonstra R, Bosga-Bouwer A, Mastik M, et al. Identification of chromosomal copy number changes associated with transformation of follicular lymphoma to diffuse large B-cell lymphoma [J]. Hum Pathol, 2003,34(9):915-923.
  • 5Reed JA, Loganzo F Jr, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression [J]. Cancer Res, 1995,55 (13):2713-2718.
  • 6Chhanabhai M, Krajewski S, Krajewska M, et al.Immunohistochemical analysis of interleukin-1beta-converting enzyme/Ced-3 family protease, CPP32/Yama/Caspase-3, in Hodgkin's disease [ J ]. Blood, 1997,90 (6): 2451-2455.
  • 7Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands [J]. Curr Opin Immunol, 1994,6(3) :407-413.
  • 8Ju ST, Panka DJ, Cui H, et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation [J]. Nature, 1995,373(6513):444-448.
  • 9Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand [J]. Cancer Res, 1997,57(6): 1007-1012.
  • 10O'Connell J, O'Sullivan GC, Collins JK, et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand [J]. J Exp Med, 1996,184(3):1075-1082.

二级参考文献2

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部